NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced significant financial losses.
Celcuity Announces Unexpected Delayed Drug Launch
On July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured FDA approval for its breast cancer therapy Revtorpyk (gedatolisib) and "anticipates commercial launch in late Q3 2026", representing a delayed launch timeline relative to analyst expectations. Commenting on the announcement, a Stifel analyst noted that "late 3Q26 launch guidance seems somewhat extended." A Leerink analyst agreed, noting that while the "approval was largely expected . . . we did not anticipate [a Q3 launch date] given prior commentary on launch readiness."
Celcuity’s Stock Drops Over 17%
